argenx SE (MEX:ARGXN) Inventories, Work In Process: MXN0 Mil (As of Mar. 2026)


MEX:ARGXN argenx SE MEX:ARGXN
63 GF Score
Price MXN13,000.67
GF Value MXN20,951.12
! 5 Warning Signs
View Full Analysis

What is argenx SE Inventories, Work In Process?

argenx SE MEX:ARGXN 63 Inventories, Work In Process is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:ARGXN with a GF Score™ of 63/100 and a GF Value™ of MXN20,951.12. The stock has 5 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. argenx SE's work in process for the quarter that ended in Mar. 2026 was MXN0 Mil.

argenx SE Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for argenx SE's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Inventories, Work In Process Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 773.48 1,267.55 799.05 549.69 999.95

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 225.14 0.00 999.95 0.00
MEX:ARGXN
63GF Score
argenx SE MEX:ARGXN
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of MXN0 Mil mean?
argenx SE (MEX:ARGXN) has a Inventories, Work In Process of MXN0 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on argenx SE and its competitors.
Is argenx SE's Inventories, Work In Process too high?
argenx SE's current Inventories, Work In Process is MXN0 Mil. Overall, argenx SE has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Inventories, Work In Process compare to VRTX and REGN?
argenx SE's Inventories, Work In Process of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on argenx SE and its competitors. argenx SE's current Inventories, Work In Process is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
argenx SE (MEX:ARGXN) has a current Inventories, Work In Process of MXN0 Mil. The stock's GF Value™ is MXN20,951.12, compared to a current price of MXN13,000.67 — trading 37.9% below its estimated fair value. The current Inventories, Work In Process is MXN0 Mil. argenx SE's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For argenx SE (MEX:ARGXN), the current Inventories, Work In Process is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (MEX:ARGXN) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of MXN13,000.67 is trading 37.9% below its estimated GF Value™ of MXN20,951.12.

Key valuation signals for MEX:ARGXN:

  • Inventories, Work In Process: MXN0 Mil
  • GF Value™: MXN20,951.12 vs. price of MXN13,000.67 (37.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the MEX:ARGXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
63GF Score

Get the complete analysis for MEX:ARGXN

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN13,000.67
Price
MXN20,951.12
GF Value